Table 1 Clinical characteristics and age distribution of study samples (serum samples) used for E2F5 and CA125 expression studies.
From: E2F5 status significantly improves malignancy diagnosis of epithelial ovarian cancer
| Â | Number of cases | Age | Cancer subtypes | ||||
|---|---|---|---|---|---|---|---|
| Â | Â | Â | Serous carcinoma | Mucinous carcinoma | Endometroid carcinoma | Clear cell carcinoma | Others* |
Normal | 56 | 45.00 ± 15.00 |  |  |  |  |  |
Benign | 40 | 42.80 ± 16.65 | 5 | 11 | 14 | 0 | 10 |
Stage I/II | 16 | 50.94 ± 12.16 | 2 | 4 | 6 | 3 | 1 |
Stage III/IV | 32 | 52.32 ± 10.11 | 19 | 1 | 9 | 3 | 0 |